Safety and Tolerability of the Dual 5-Alpha Reductase Inhibitor Dutasteride in the Treatment of Androgenetic Alopecia.

CONCLUSION: Dutasteride 0.5 mg is to be well-tolerated in 18 to 41 years old AGA patients in a clinical practice environment. PMID: 27489426 [PubMed]
Source: Annals of Dermatology - Category: Dermatology Tags: Ann Dermatol Source Type: research